Key points are not available for this paper at this time.
Passiflora alata Curtis is increasingly recognized for its potential therapeutic applications, especially in treating CNS disorders.However, comprehensive studies evaluating its safety and convulsion efficacy are limited.This study aimed to examine the anticonvulsive activity of P. alata using in vitro and in vivo assays.Ellman's colourimetric method was used for the AchE inhibition assay, and pentylenetetrazole (PTZ) and maximum electroshock (MES)-induced convulsions model were used to determine the in vivo anticonvulsion activity.Acute toxicity (OECD-423) testing proved no harmful effects of P. alata.In vitro AchE inhibition assay revealed that the P. alata leaf methanol extract (PLM) showed better inhibition.In a PTZ-induced seizure model study, PLM outperformed in anticonvulsant efficacy, evidenced by delayed seizure onset, shorter convulsion durations, and higher survival rates.PLM, at 400 mg/kg body weight dose, showed dosedependent anticonvulsant antioxidant activity by altering SOD, CAT, and MDA levels.Partial restoration of neurotransmitter (Ach) levels, with limited impact on dopamine, was also seen.Histopathological evaluations suggest potential neuroprotective benefits.In conclusion, P. alata, particularly at a dose of 400 mg/kg, exhibits promising anticonvulsant properties, antioxidant activity, and neuroprotective potential, warranting further investigation into its use as an adjunct or alternative therapy in seizure management.Additional research is required to understand their therapeutic processes and long-term efficacy fully.
Lodhi et al. (Mon,) studied this question.